Service Hotline: 400-826- 0806

News center


Kang Mei Pharmaceutical Ranked 167 in Forbes Global Enterprise 2000 for the Fourth Consecutive Year

Date: 2018-06-12
Views: 50

On June 7th, Forbes Magazine released the list of "Global Listed Companies 2000" in 2018 (Forbes Global 2000). Kangmei Pharmaceutical's strong performance in 2017 market value, as well as its operating income, profit, asset size and other items The steady increase in performance ranked 1320 companies worldwide. This is the first time since 2015 that Kangmei Pharmaceutical has been ranked in the list for the fourth time in a row. This year's ranking has risen sharply by 167 from 1487 last year, which is a strong rise of 583 compared with 1913 when it was first selected.

According to reports, Forbes magazine selects “2000 Global Listed Companies” every year. This list is regarded as one of the most authoritative and most-respected business companies in the world, ranked by operating income, profit, assets and market value. The overall score is based on. Kangmei Pharmaceutical ranks in the forefront of the global pharmaceutical industry with its revenue of US$4.3 billion, profit of US$672 million, assets of US$11.5 billion and market capitalization of US$19.4 billion.

Kangmei Pharmaceutical's performance in 2017 is eye-catching and is not unrelated to a good policy environment. In 2017, Chinese pharmaceutical industry policies continued to be favorable and became an important opportunity for the development of the enterprise: the "Chinese Medicine Law" was formally implemented; the Nineteenth National Congress report regards the "transmission of the development of traditional Chinese medicine" as an important task in the implementation of a healthy Chinese strategy; at the same time, Policies involving pharmaceuticals, medical care, medical insurance and circulation have also gradually landed. The pharmaceutical industry is reshaping the pattern and industry consolidation has accelerated at the same time.

From the standpoint of Kangmei's own construction and operation, 2017 coincides with the 20th anniversary of the establishment of Kangmei Pharmaceutical. After a deep accumulation in the Chinese medicine industry, Kangmei Pharmaceutical has now become a more complete business chain in the domestic Chinese medicine industry, and it has a healthier medical resource. One of the companies with rich and integrated capabilities, the integrated operation model and business system of the entire industrial chain of TCM has been formed.

At present, Kangmei Pharmaceutical's production and sales scale of Chinese Herbal Medicines ranks first in the industry. It has successively built 17 traditional Chinese medicine decoction pieces and modern pharmaceutical production bases, established over 100,000 mu of standardized planting bases throughout the country, and established more than 30 modern pharmaceutical warehousing logistics centers. The modern and three-dimensional production and supply chain system of medicinal herbs and Chinese herbal medicines has provided quality products for hospital customers, Chinese patent medicine production customers, retail channel customers and even end consumers. At the same time, Kangmei Pharmaceutical has mastered the right to speak in the industry through the well-operated Chinese herbal medicine market and the establishment of a trading platform for Chinese herbal medicines. The strategy of Kangmei Pharmaceutical is also based on the whole industry chain of traditional Chinese medicine based on TCM decoction pieces, and realizes the layout of the "smart +" health industry. It not only wins hospitals and pharmaceutical logistics extensions, but also uses "Internet +". With ease, Kangmei Smart pharmacy has made rapid progress in its business and has reached cooperation with hundreds of medical institutions in important cities such as Guangzhou, Shenzhen, Beijing and Chengdu, Kunming, and Guiyang. It has also been promoted as an industry standard for national demonstration and promotion.

As the leading enterprise of Chinese Herbal Pieces, Kangmei Pharmaceutical has maintained a good growth performance since its listing. As of 2017, the company's net profit has grown for the 16th consecutive year. On May 15th, 2018, Kangmei Pharmaceutical successfully entered the market. Among the 234 A shares that were included in the MSCI index system, Kangmei Pharmaceutical was the highest-valued Chinese medicine company with a promising development prospect in the international market. According to consulting data from Wind, from May 15 to June 2, Hong Kong Securities Clearing Company Limited purchased 912.63 million shares of the company through land share exchanges, and its shareholding ratio increased from 0.44% to 0.64%, resulting in a net inflow of land exchange funds. 2.26 billion yuan. Accelerated entry of overseas funds has driven the market value of Comtech Pharmaceuticals to a record high.

Ma Xingtian, chairman and president of Kangmei Pharmaceutical, said that Kangmei Pharmaceutical will further approach the terminal in the future, shorten the distance with consumers, and promote the deep C-term of Kangmei brand. The company will focus on the innovative mode of “Smart Pharmacy + Smart Medicine Cabinet” and will deliver a wealth of its own products to the C-side to create the “Kangmei” brand. The company will also conduct more explorations in the areas of health services such as Chinese medicine rehabilitation and wisdom medical care, and build a multi-level and diversified medical service structure. In the future, through "big data" precipitation support, we will strengthen the research and development of new products, especially new drugs, seize the first-mover advantage, and strengthen the core competitiveness of Kangmei Pharmaceutical.


News / Related news More
2017 - 12 - 04
Yongquan Forum and Baishaquan · ZUFE Strategic Cooperation Signing Ceremony were held on the afternoon of 3rd December at Baishaquan M&A Block. Yongquan Forum is a major communication and project paring brand created by Baishaquan M&A Block. By hold sharing session and salon or giving speech each month, the forum serves as a communication platform for industry leaders with certai...
2017 - 11 - 30
CAI Gangqing, president and deputy secretary of the Party Committee of Anji Industrial Investment Development Group (IIDG) paid a visit to TTGG with 5 colleagues on the afternoon of 30th November. ZOU Jin, general manager and deputy secretary of the Party Committee of IIDG, FANG Jun, vice-general manager, and other department heads of IIDG attended the discussion. Our managing partner ZHANG Y...
2017 - 11 - 28
Zvi Heifetz, Israeli Ambassador to China, paid a visit to TTGG along with his wife on the evening of 28th November 2017. They were greeted by TTGG’s president YU Baohong. ZHANG Yu and GUO Feng, managing partners of TTGG, LI Xiang, general-manager of Investment Management Department, and other department heads also took part in the meeting.After greeting, YU briefly introduced TTGG’s hist...
2017 - 08 - 14
With the accelerating rhythm of the society, more and more white-collars are feeling stressed under modern work environments. In fact, such stress primarily results from the target-oriented time management. The key factors facilitating their abilities to improve time management efficiency and effectiveness are: how to find the causes of inefficiency, how to distinguish between the important things...
Copyright © 2016 - 2019 Zhejiang Paradise Silicon Valley Asset Management Group Co., Ltd










  • 400-826-0806